Sign in

RKTO on Nasdaq

Rocket One Inc.

Rocket One Inc. is an American pharmaceutical preparations company based in New York.1 Its shares trade on Nasdaq under the symbol RKTO.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerRKTO on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersHoboken, New Jersey1
  • Incorporated inNV2
  • Business address720 Monroe Street, Suite E514, Hoboken, Nj 070302
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

(HT-004); and (iii) a treatment for obesity, and obesity-related diseases and conditions (HT-VA).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$12.4M in 2025+60% since 2019
-$15.0M-$10.0M-$5.0M02019: -$7.7M-$7.7M20192020: -$7.3M-$7.3M2020−5%2021: -$14.1M-$14.1M2021+93%2022: -$11.1M-$11.1M2022−22%2023: -$8.0M-$8.0M2023−28%2024: -$8.2M-$8.2M2024+3%2025: -$12.4M-$12.4M2025+50%
Net income456789-$12.5M in 2025+62% since 2019
-$15.0M-$10.0M-$5.0M02019: -$7.7M-$7.7M20192020: -$7.2M-$7.2M2020−7%2021: -$14.3M-$14.3M2021+99%2022: -$11.4M-$11.4M2022−21%2023: -$8.1M-$8.1M2023−29%2024: -$8.2M-$8.2M2024+1%2025: -$12.5M-$12.5M2025+52%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development expenses$5.9M$3.2M
General and administrative expenses$6.4M$5.0M
Total operating expenses$12.4M$8.2M
LOSS FROM OPERATIONS-$12.4M-$8.2M
Change in fair value of investment in joint venture-$581
Unrealized loss on crypto assets-$108.6K
Dividend and interest income$680$27.7K
Total other (expenses) income, net-$108.0K$27.1K
NET LOSS-$12.5M-$8.2M
Basic-$0.90-$1.28
Diluted-$0.90-$1.28
Basic13.8M shares6.4M shares
Diluted13.8M shares6.4M shares
Foreign currency translation adjustment$1.8K-$18.2K
Total comprehensive loss-$12.5M-$8.2M

Compare Rocket One Inc. with another company

Corporate structure

Rocket One Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Rocket One Inc.

  • Rocket One Inc. Hoboken, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Rocket One Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$4.7K9 Dec 31, 2025$31.1K9 Dec 31, 2024−85.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.2M9 Dec 31, 2025$7.0M9 Dec 31, 2024−11.2%

Properties, in its own words

Our executive office is located at 720 Monroe Street, E514, Hoboken, NJ 07030 which we rent for approximately $1,960 per month pursuant to a lease which expires on December 31, 2026. We believe that our existing facilities are suitable and adequate to meet our current needs. We intend to add new facilities or expand existing facilities as we add employees, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.

Item 2 of the 10-K filed Mar 27, 2026.3

Leadership

Who has led Rocket One Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Robb Knie2019–now

President

  1. Robb Knie2019–now

Chief financial officer

  1. David S. Briones2019
20202025
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorDavid Sarnoff named Jan 4, 202322

Former names

  • Hoth Therapeutics, Inc.Jul 14, 2017 to May 27, 20262

Timeline

  1. Sep 25, 20268-K Director nominations; Other events23
  2. Sep 22, 20268-K Other events24
  3. Aug 11, 20268-K Listing notice or transfer; Other events25
  4. Jul 31, 20268-K Other events26
  5. Jul 21, 20268-K Other events27
  6. Jun 25, 20268-K Other events28
  7. Jun 3, 20268-K Other events29
  8. Jun 3, 20268-K Other events30
  9. Jun 2, 20268-K Other events31
  10. May 28, 20268-K Other events32
  11. May 27, 20268-K Bylaws or fiscal year changed; Other events33
  12. May 21, 20268-K Entered a material agreement; Other events34
  13. Feb 15, 2019New chief executive Robb Knie becomes CEO12

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/202635

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

175 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 34 insider forms, 7 large holders, 1 private raises, 52 other. The latest 20:

  1. Oct 2, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  2. Sep 25, 20268-K CURRENT REPORT EDGAR
  3. Sep 22, 20268-K CURRENT REPORT EDGAR
  4. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  5. Aug 11, 20268-K CURRENT REPORT EDGAR
  6. Jul 31, 20268-K CURRENT REPORT EDGAR
  7. Jul 31, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  8. Jul 21, 20268-K CURRENT REPORT EDGAR
  9. Jun 25, 20268-K CURRENT REPORT EDGAR
  10. Jun 3, 20268-K CURRENT REPORT EDGAR
  11. Jun 3, 20268-K CURRENT REPORT EDGAR
  12. Jun 3, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  13. Jun 2, 20268-K CURRENT REPORT EDGAR
  14. May 28, 20264 EDGAR
  15. May 28, 20264 EDGAR
  16. May 28, 20264 EDGAR
  17. May 28, 20264 EDGAR
  18. May 28, 20264 EDGAR
  19. May 28, 20268-K CURRENT REPORT EDGAR
  20. May 27, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR

The 175 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 16, 2024Knie RobbCEO and PresidentBuy25,000$0.67$16.8KForm 4
Sep 19, 2022Knie RobbCEO and PresidentBuy10,000$0.39$3.9KForm 4
Sep 16, 2022Knie RobbCEO and PresidentBuy10,000$0.40$4.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Robb Knie56$450.0K$1.2M41
2023Chief Executive Officer and President$450.0K$846.3K41

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$10.0M 2023–2023
Money received by yearMoney received by year, 2023–2023: $10.0M in all. Private raises (Form D) $10.0M.$0$2.5M$5M$7.5M$10M2023 · Private raises (Form D): $10.0M2023
Figures by year
YearPrivate raises (Form D)Total
2023$10.0M$10.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jan 3, 2023Raised $10 million in a private offering of equity22 Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC683,291$683.3K0.0%+553,600
Jane Street Group, LLC219,316$219.3K0.0%New
UBS Group AG211,304$211.3K0.0%+53,327
Geode Capital Management, LLC195,982$196.0K0.0%−18,262
Vanguard Fiduciary Trust Co84,318$84.3K0.0%No change
State Street Corp63,939$63.9K0.0%No change
LPL Financial LLC41,029$41.0K0.0%New
Northern Trust Corp38,724$38.7K0.0%−3,330
Susquehanna International Group, Llp25,966$26.0K0.0%New
Lido Advisors, LLC19,500$19.5K0.0%−19,500
Morgan Stanley10,006$10.0K0.0%No change
Charles Schwab Trust Co10,000$10.0K0.0%New
SBI Securities Co., Ltd.4,517$4.5K0.0%+4,506
Farther Finance Advisors, LLC4,237$4.2K0.0%New
Osaic Holdings, Inc.2,701$2.7K0.0%No change
Tower Research Capital LLC (TRC)2,005$2.0K0.0%−5,350
Federation des caisses Desjardins du Quebec350$3430.0%No change
Jones Financial Companies Lllp100$950.0%−400
Mcguire Capital Advisors Inc50$500.0%New
IFP Advisors, Inc45$450.0%No change
Royal Bank Of Canada240$00.0%−630

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Rocket One Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRocket One Inc.1
  • CIK0001711786
  • Employer ID (EIN)82-15537943
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address720 Monroe Street, Suite E514, Hoboken, NJ 070301
  • Phone(866) 239-74591
  • Shares outstanding24,897,581 as of Aug 14, 202611
  • Public float$15.4M as of Jun 30, 20253
  • AuditorWithumSmith+Brown, PC, East Brunswick, New Jersey PCAOB ID 100; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJul 14, 20171
  • Filings349 in all: 8-K (97), 4 (55), 10-Q (23), CORRESP (22), UPLOAD (16), 424B5 (15), 3 (14), EFFECT (11)1
    All 31 form types

    S-1/A (10), SC 13G (9), 10-K (8), 424B3 (8), DEF 14A (7), SC 13G/A (7), D (6), S-3 (6), 5 (5), DEFA14A (5), S-1 (5), S-8 (5), PRE 14A (4), ARS (2), 4/A (1), 424B4 (1), 8-A12B (1), CERT (1), CT ORDER (1), DEFR14A (1), DRS (1), DRS/A (1), DRSLTR (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Jun 16, 2025
    Latest 8-K (8-K) Sep 25, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareHOTHNasdaq

From the cover page of the 10-K filed Mar 27, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Rocket One Inc. names in Item 1A of its 10-K filed Mar 27, 2026: 57 risks under these headings, as written.3

  • Risks Related to Our Financial Position, Financial Reporting Matters and Need for Capital
  • We have generated no revenue from commercial sales to date and our future profitability is uncertain.
  • If we fail to obtain the capital necessary to fund our operations, we will be unable to continue or complete our product development and you will likely lose your entire investment.
  • Even if we can raise additional funding, we may be required to do so on terms that are dilutive to you.
  • Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.
  • Risks Related to Product Development, Regulatory Approval, Manufacturing and Commercialization
  • We are dependent upon the clinical success of our licensed products and technologies. If we are unable to generate revenues from our licensed products and technologies, our ability to create shareholder value may be limited.
  • The marketing approval process of the FDA is lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for the product candidates we intend to develop, our business may be substantially harmed.
  • We may encounter substantial delays in completing our clinical studies which in turn will require additional costs, or we may fail to demonstrate adequate safety and efficacy to the satisfaction of applicable regulatory authorities.
  • If we are not able to obtain any required regulatory approvals for our product candidates, we will not be able to commercialize our product candidates and our ability to generate revenue will be limited.
  • If we are unable to submit an application for product candidate approval under Section 505(b)(2) of the FDCA or if we are required to generate additional data related to the safety and efficacy of a product candidate in order to obtain approval under Section 505(b)(2), we may be unable to meet our anticipated development and commercialization timelines.
  • We may not be able to obtain or maintain ODD or exclusivity for our product candidates.
The other 46 risks
  • Modifications to our products may require new drug approvals.
  • Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.
  • Additional delays to the completion of clinical studies may result from modifications being made to the protocol during the clinical trial, if such modifications are warranted and/or required by the occurrences in the given trial.
  • There can be no assurance that the data generated from our clinical trials using modified protocols will be acceptable to FDA.
  • We rely on and intend to rely on third-parties to conduct our clinical trials and to assist us with pre-clinical development. If these third-parties do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize our products.
  • We rely on and intend to rely on third parties to manufacture our clinical product supplies, and to produce and process our product candidates, if approved. Our commercialization of any of our product candidates could be stopped, delayed, or made less profitable if those third parties fail to obtain approval of government regulators, fail to provide us with sufficient quantities of drug product, devices, or device components, or fail to do so at acceptable quality levels or prices.
  • The future results of our current or future clinical trials may not support our product candidate claims or may result in the discovery of unexpected adverse side effects.
  • Even if our product candidates are approved by regulatory authorities, if we or our suppliers fail to comply with ongoing FDA regulations or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.
  • Our revenue stream will depend upon third-party reimbursement.
  • Current and future legislation and other regulatory reform measures may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, affect the prices we may obtain for such product candidates and may have a negative impact on our business and results of operations.
  • We are dependent on third parties for manufacturing and marketing of our proposed product candidates. If we are not able to secure favorable arrangements with such third parties, our business and financial condition could be harmed.
  • We may have conflicts with our partners that could delay or prevent the development or commercialization of our product candidates.
  • Even if we receive regulatory approval for any of our product candidates, we may not be able to successfully commercialize the product and the revenue that we generate from its sales, if any, may be limited.
  • Our products will face significant competition, and if they are unable to compete successfully, our business will suffer.
  • Adverse events involving our products may lead the FDA or other regulatory agencies to delay or deny clearance for our products or result in product recalls that could harm our reputation, business and financial results.
  • If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be adversely affected.
  • If a third-party contract manufacturing organization (“CMO”) upon whom we rely to formulate and manufacture our product candidates does not perform, fails to manufacture according to our specifications or fails to comply with strict regulations, our pre-clinical studies or clinical trials could be adversely affected, and the development of our product candidates could be delayed or terminated, or we could incur significant additional expenses.
  • In the event that we need to change our CMOs, our pre-clinical studies, clinical trials or the commercialization of our product candidates could be delayed, adversely affected or terminated, or such a change may result in significantly higher costs.
  • Healthcare Reform in the United States.
  • Our business may be adversely affected by cybersecurity threats, information systems interruptions and/or threats to our physical buildings.
  • Risks Related to Our Intellectual Property Rights
  • We rely upon licenses granted to us by various licensors, and if such licensors do not adequately defend such licenses, our business may be harmed.
  • Our business depends upon us securing and protecting critical intellectual property.
  • Patent positions in our industry are highly uncertain and involve complex legal and factual questions.
  • If we are found to be infringing on patents or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue the development or sale of our products, and/or pay damages.
  • Our ability to protect and enforce any patents we may obtain does not guarantee that we will secure the right to commercialize such patents.
  • We rely on confidentiality agreements to protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become known to our competitors.
  • Risks Related to the Company
  • We have expanded and may continue to expand our business through the acquisition of rights to new drug candidates that could disrupt our business, harm our financial condition and may also dilute current shareholders’ ownership interests in our Company.
  • Any international operations we undertake may subject us to risks inherent with operations outside of the United States.
  • We may not be successful in hiring and retaining key employees, including executive officers.
  • Managing our growth as we expand operations may strain our resources.
  • If a product liability claim is successfully brought against us for uninsured liabilities, or such claim exceeds our insurance coverage, we could be forced to pay substantial damage awards that could materially harm our business.
  • Our business may be adversely affected by public health crises, such as pandemics and epidemics, which may have a material adverse effect on our business.
  • Significant disruptions of information technology systems or breaches of data security could adversely affect our business.
  • Risks Related to Our Common Stock
  • The price of our common stock may fluctuate substantially.
  • We may acquire other companies or technologies which could divert our management’s attention, result in dilution to our shareholders and otherwise disrupt our operations and adversely affect our operating results.
  • Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business, financial condition and stock price.
  • Future sales and issuances of our securities could result in additional dilution of the percentage ownership of our shareholders and could cause our share price to fall.
  • We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares.
  • We are a “smaller reporting company”, and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
  • We may be at risk of securities class action litigation.
  • We are currently listed on The Nasdaq Capital Market (“Nasdaq”). If we are unable to maintain listing of our securities on Nasdaq or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our shareholders to sell their securities.
  • Our Articles of Incorporation, as amended (“Articles of Incorporation”), our Amended and Restated Bylaws, and Nevada law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline.
  • Our Amended and Restated Bylaws provide that the Eighth Judicial District Court of Clark County, Nevada will be the sole and exclusive forum for certain disputes which could limit shareholders’ ability to obtain a favorable judicial forum for disputes with us or its directors, officers, employees or agents.
  • General Risk Factors
  • If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our stock price and trading volume may decline.
  • Financial reporting obligations of being a public company in the United States are expensive and time-consuming, and our management will be required to devote substantial time to compliance matters.
  • Failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock. If our internal controls are not effective, we may not be able to accurately report our financial results or prevent fraud.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
    SEC EDGAROther events
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
    SEC EDGAROther events
  28. 28
    SEC EDGAROther events
  29. 29
    SEC EDGAROther events
  30. 30
    SEC EDGAROther events
  31. 31
    SEC EDGAROther events
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41